How to Use Latisse
This is an article written by Troy Bedinghaus, O.D. on how to use Latisse. Find his article here.
Latisse is a prescription treatment for hypotrichosis and the growth of eyelashes. Regular application of Latisse will make your eyelashes longer, thicker and darker. Most people see results within two months of continued use. Here’s how to safely apply Latisse to enhance your own eyelashes. Of course, only use Latisse if it has been prescribed for you by your doctor (never borrow a friend’s prescription).
Time Required: Minutes
- Each night, begin by cleaning your face. Be sure to remove your makeup and contact lenses.
- Select a new applicator from the tray. Holding the new, sterile applicator horizontally, place one drop of Latisse solution onto the tip of the applicator.
- Immediately and carefully draw the applicator across the skin of your upper eyelid where the lashes meet the skin. Glide the applicator from the inner to the outer part of your lash line.
- Using a tissue or cotton round, blot any excess solution beyond the eyelid margin.
- Dispose of the used applicator. Repeat the process with a new applicator for your other eye.
- Never use the same applicator for both eyes. This helps to minimize possible contamination between your eyelids.
- Do not apply Latisse solution to the lower eyelids.
- Use only the sterile applicators that come with Latisse.
- Wait 15 minutes after applying Latisse to reinsert contact lenses.
- If you miss a night of application, simply wait until the next evening. Don’t try to “catch up.”
What You Need
- Latisse solution
- Blotting tissues
Great post on Allergan’s development of Latisse ® for other uses. See the original post HERE.
posted by Colin Stewart
August 16th, 2011, 6:00 am
Botox maker Allergan has begun Phase 2 clinical trials of a possible hair-growth treatment for men and women based on the active ingredient in its drug Latisse ®, which stimulates the growth of eyelashes.
The Irvine-based company has already conducted Phase 1 clinical trials, which tested the safety and stability of the medication, said Scott Whitcup, Allergan’s chief scientific officer and executive vice president of research and development.
Two separate sets of Phase 2 clinical trials are under way to measure how well the drug, bimatoprost, works to fight male-pattern baldness in men and hair-thinning in women, he said. Results could be available by late 2012.
“We see a potential market not only for male-pattern baldness, which is a huge market, but … for female hair thinning, that could be a very beneficial product as well,” Whitcup said in a recent conference call with stock analysts.
In one clinical trial, Allergan is recruiting 300 men who suffer from male-pattern baldness. They will test how well bimatoprost works at three different strengths in comparison to an inactive solution and to minoxidil (Rogaine).
For the second clinical trial, Allergan is recruiting 300 women who suffer from female-pattern hair thinning for a similar test.
Whitcup said he didn’t expect early FDA approval of Allergan’s potential hair treatment. After the Phase 2 trials are completed next year, the agency will require two more Phase 3 trials, he said.
That final set of tests is used to confirm a drug’s “effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely,” according to the National Library of Medicine.
In 2008, the FDA approved bimatoprost, which is sold under the name Latisse ®, as a treatment for sparse eyelashes, with a warning that it can cause hair growth on other parts of the body that come in contact with the drug. Some doctors have already tried using Latisse ® as an “off-label” treatment for hair loss.